Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Cash from Financing Activities Cash from Financing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased

Daily Values

Growth Metrics

Others

Fennec Pharmaceuticals (FENC) Capital Expenditures (2024)

Fennec Pharmaceuticals filings provide 1 years of Capital Expenditures readings, the most recent being $1.7 million for Q1 2024.

On a quarterly basis, Capital Expenditures changed N/A to $1.7 million in Q1 2024 year-over-year; TTM through Jun 2024 was $1.7 million, a N/A change, with the full-year FY2022 number at $175000.0, changed N/A from a year prior.
Capital Expenditures hit $1.7 million in Q1 2024 for Fennec Pharmaceuticals.
In the past five years, Capital Expenditures ranged from a high of $1.7 million in Q1 2024 to a low of $1.7 million in Q1 2024.